Clone UC104F1011 is widely used in in vivo mouse studies to neutralize murine CTLA4 (CD152), thereby blocking CTLA4mediated inhibition of T cell activation and promoting immune responses, most frequently in immunology and immunooncology research.

Key in vivo applications of clone UC104F1011 in mice include:

• Blocking CTLA4: The antibody binds to CTLA4 (CD152) on T cells, preventing CTLA4 from interacting with B7 ligands (CD80/CD86) on antigenpresenting cells. This blockade removes inhibitory signaling, augmenting T cell activation and proliferation.
• Promotion of T cell costimulation: By allowing CD28 to interact with B7 ligands unopposed by CTLA4, UC104F1011 enhances costimulatory signaling necessary for robust immune activation.
• Research in immunooncology: The antibody is extensively used to study and model immune checkpoint blockade therapy in mice, especially in cancer models where researchers assess antitumor immunity when CTLA4driven inhibition is suppressed.
• Inflammatory and infectious disease models: Since CTLA4 is a critical immune regulator, this clone is used in models of autoimmune, infectious, and inflammatory diseases to study the consequences of enhanced T cell activation.
• Experimental immune modulation: The antibody is used to intentionally disrupt T cell inhibitory pathways to explore basic mechanisms of immune regulation or to enhance the efficacy of vaccines and adoptive cell therapies.

Additional applications (sometimes overlapping with in vitro use) include flow cytometry detection of mouse CTLA4 on activated T cells, and validation in functional assays demonstrating T cell activation.

In summary, UC104F1011 is a standard tool for in vivo blockade of CTLA4 in mice to model and dissect T cellmediated immune activation and checkpoint inhibition in a variety of disease contexts.

Commonly used antibodies or proteins paired with UC104F1011 (an antimouse CTLA4 clone) in the literature include a range of T cell, immune checkpoint, and phenotyping antibodies, as well as isotype and experimental controls. The most frequently coused antibodies and proteins are:

• Other antiCTLA4 clones: For comparative studies, other antiCTLA4 clones such as 9H10 and 9D9 are often referenced and used alongside UC104F1011.
• Isotype controls: Armenian hamster IgG isotype controls are commonly used to match the species and isotype of UC104F1011 for specificity and background checks.
• AntiCD28: Used to study costimulatory pathways alongside CTLA4 signaling for T cell activation experiments.
• T cell phenotyping antibodies (for flow cytometry or cell sorting), such as:
  • AntiCD3 (e.g., clone 1452C11)
  • AntiCD4 (e.g., clone RM45; CyChrome or PerCPconjugated)
  • AntiCD8 (e.g., clone 536.7)
  • AntiCD25 (biotinylated, e.g., clone 7D4)
  • AntiCD45 (e.g., CD45RB FITC, clone 16A; or CD45.2 FITC, clone 104)
  • AntiB220 (clone RA36B2)
  • AntiMac1 (clone M1/70)
  • AntiMHC class II (clone TIB120)
• TGFβ neutralizing antibodies (e.g., clone 1D11.16.8) in studies involving immune regulation pathways.
• Detection reagents: PE or FITCconjugated secondary reagents, such as PEstreptavidin or BD Fc Block™ to prevent nonspecific Fc receptor binding in flow cytometry.
• Control IgG: Control hamster or rat IgG of matching subtypes for rigor in interpreting results.

The specific combination depends on the experiment, such as tumor immunity studies (using broader immune phenotyping and checkpoint controls), or T cell functional assays focusing on coinhibitory/costimulatory signaling pathways.

Key findings from scientific literature on clone UC104F1011 (an antimouse CTLA4 monoclonal antibody) can be summarized as follows:

• CTLA4 Blockade and T Cell Costimulation: Clone UC104F1011 is used extensively to neutralize murine CTLA4 (CD152), blocking its inhibitory action, and thus promoting T cell costimulation by preventing CTLA4 from binding B7 coreceptors and allowing CD28 binding instead.

• Applications and Functionality: The antibody is welldocumented for both in vitro and in vivo studies, allowing for detection of CTLA4 via flow cytometry and Western blot, as well as for functional immune assays. It is particularly cited as being useful for flow cytometry, distinguishing it from some other clones.

• Neutralizing without Depleting Tregs: Unlike some CTLA4 antibodies (such as clone 9H10), UC104F1011 does not typically deplete regulatory T cells (Tregs) via antibodydependent cellular cytotoxicity (ADCC). Instead, its main action is CTLA4 blockade rather than Treg depletion, which impacts comparative outcomes in tumor immunotherapy studies.

• Antitumor and Immunological Effects: Across different CTLA4 antibodies, antiCTLA4 therapy (including with UC104F1011) is associated with enhanced memory T cell generation, increased cytokine production, and improved antitumor responses compared to antiPD1 therapy. However, antibodyspecific features such as Treg depletion potency differentiate clones' efficacy in rechallenge tumor models.

• Specificity and Epitope Recognition: UC104F1011 is a hamster IgG that binds a precise epitope on mouse CTLA4, which is a member of the Ig superfamily and an immune checkpoint responsible for immune downregulation. It is routinely used to study immune checkpoint pathways in preclinical models.

• Immunological Mechanisms: Scientific studies using UC104F1011 have revealed that:

  • CTLA4 signaling is essential for Treg function.
  • Blockade of CTLA4 promotes immune cell infiltration and metabolic fitness, particularly in glycolysislow tumors.
  • Its action is crucial for understanding both the intrinsic and extrinsic effects of CTLA4 inhibition in immune response modulation.

• Applications in Research: UC104F1011 is favored for basic immunology research, mechanistic studies, and mouse tumor models where neutralization of CTLA4 function—rather than Treg depletion—is the primary goal.

In summary, UC104F1011 is a standard tool for blocking CTLA4 in mouse immunological studies, enabling researchers to dissect T cell costimulation, immune checkpoint function, and antitumor immunity in a neutralizing, nonTregdepleting fashion.

Dosing regimens for clone UC104F1011 (antimouse CTLA4) in mouse models typically fall within a range of 50–250 µg per mouse per dose, but exact regimens are highly dependent on mouse strain, experimental context, and disease model. Commonly published protocols use 100 µg per mouse administered intraperitoneally (i.p.) at multiple discrete time points, while some preclinical studies use higher doses adjusted by weight, such as 20 mg/kg.

Key dosing regimens across different models:

• General in vivo studies: Recommended range is 50–250 µg/mouse/administration.
• Tumor models (e.g., C57BL/6 with B16 melanoma):
  • 100 µg/mouse i.p. on days 4, 7, and 10 posttumor inoculation.
  • Alternative tumor studies used 20 mg/kg (noting that for a 20g mouse, this is approximately 400 µg/mouse).
• Immunization/autoimmunity models:
  • 100 µg/mouse given at three time points surrounding immunization (e.g., days 3, 4, and 5 after antigen exposure).

Additional considerations:

• Dosing frequency (single vs multiple doses) and timing (relative to disease induction or immunization) are tailored per protocol.
• Higher doses or increased frequency may be used for aggressive tumor models or combination treatments, while immune priming studies may use lower total doses.
• Dose may be adjusted based on body weight in some studies, especially for pharmacokinetic consistency in diverse strains.

Summary Table:| Mouse Model / Experimental Context | Typical Dose and Schedule ||||| General in vivo (various strains) | 50–250 µg/mouse per dose || C57BL/6, B16 melanoma (tumor) | 100 µg/mouse i.p. on days 4, 7, and 10 || Tumor models (weightbased) | 20 mg/kg (≈400 µg for 20g mouse) || Immunization/autoimmune priming | 100 µg/mouse on 3 consecutive days |

In summary, regimens using clone UC104F1011 are generally consistent in dose (100–250 µg/mouse), but can vary by timing, frequency, and weight adjustments depending on the specific mouse strain and experimental application.